statistiche ricercatore

DENTALI, FRANCESCO

Distribuzione geografica

Continente	#
NA - Nord America	23.285
EU - Europa	9.770
AS - Asia	2.974
Continente sconosciuto - Info sul continente non disponibili	33
SA - Sud America	27
OC - Oceania	6
AF - Africa	5
Totale	36.100

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	23.258
IT - Italia	3.805
UA - Ucraina	2.282
TR - Turchia	1.607
SE - Svezia	1.188
VN - Vietnam	733
DE - Germania	673
CN - Cina	558
IE - Irlanda	534
FI - Finlandia	498
GB - Regno Unito	339
FR - Francia	196
BE - Belgio	128
RU - Federazione Russa	38
IN - India	34
EU - Europa	29
CA - Canada	23
NL - Olanda	23
JP - Giappone	13
BR - Brasile	12
CL - Cile	11
ES - Italia	9
PT - Portogallo	8
RO - Romania	7
CH - Svizzera	6
GR - Grecia	6
AT - Austria	5
AU - Australia	5
HU - Ungheria	4
A2 - ???statistics.table.value.countryCode.A2???	3
AL - Albania	3
AR - Argentina	3
EG - Egitto	3
HK - Hong Kong	3
ID - Indonesia	3
IL - Israele	3
NO - Norvegia	3
SG - Singapore	3
DK - Danimarca	2
HN - Honduras	2
IR - Iran	2
KR - Corea	2
LI - Liechtenstein	2
PL - Polonia	2
RS - Serbia	2
SI - Slovenia	2
A1 - Anonimo	1
AE - Emirati Arabi Uniti	1
AZ - Azerbaigian	1
BA - Bosnia-Erzegovina	1
CR - Costa Rica	1
CZ - Repubblica Ceca	1
KW - Kuwait	1
KZ - Kazakistan	1
LA - Repubblica Popolare Democratica del Laos	1
LK - Sri Lanka	1
LT - Lituania	1
MD - Moldavia	1
MX - Messico	1
MY - Malesia	1
NG - Nigeria	1
NZ - Nuova Zelanda	1
PE - Perù	1
PH - Filippine	1
PK - Pakistan	1
SA - Arabia Saudita	1
SK - Slovacchia (Repubblica Slovacca)	1
TH - Thailandia	1
TW - Taiwan	1
UZ - Uzbekistan	1
ZA - Sudafrica	1
Totale	36.100

Salva come PNG Salva come JPEG

Città	#
Fairfield	4.109
Milan	3.204
Woodbridge	2.674
Houston	1.923
Jacksonville	1.811
Seattle	1.575
Ashburn	1.568
Wilmington	1.493
Chandler	1.390
Cambridge	1.386
Ann Arbor	1.312
Izmir	813
Princeton	790
Dearborn	591
Nyköping	539
Dublin	533
Dong Ket	368
San Diego	244
San Mateo	159
Rome	141
Beijing	126
Brussels	123
Como	112
London	103
Düsseldorf	70
Hefei	62
Redmond	62
Nanjing	59
Philadelphia	54
Helsinki	53
Norwalk	53
Kunming	50
Verona	48
Kocaeli	39
Paris	39
Jinan	29
Nanchang	24
Boardman	22
Besana In Brianza	20
Falls Church	19
Ponte Lambro	19
Redwood City	19
Chiswick	18
Guangzhou	18
Fuzhou	17
Toronto	16
Indiana	14
Shenyang	14
Varese	14
Chicago	13
Bergamo	12
Boydton	12
Islington	12
Tokyo	11
Hebei	10
Los Angeles	10
San Francisco	10
Wuhan	10
Xian	10
Changsha	9
Dallas	9
Hanover	8
Phoenix	8
Ralingen	8
Suresnes	8
São Paulo	8
Zhengzhou	8
Chongqing	7
New York	7
Ningbo	7
Torino	7
Detroit	6
Hangzhou	6
Saint Louis	6
Amsterdam	5
Andover	5
Baotou	5
Busto Arsizio	5
New Bedfont	5
Novara	5
Parma	5
Quzhou	5
Shaoxing	5
Abbiategrasso	4
Auburn Hills	4
Budapest	4
Casorezzo	4
Chaoyang	4
Chengdu	4
Eppelborn	4
Legnano	4
Raleigh	4
Troina	4
Wallersheim	4
Wenzhou	4
Buenos Aires	3
Cairo	3
Catania	3
Cincinnati	3
Guiyang	3
Totale	28.269

Salva come PNG Salva come JPEG

Nome	#
Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis	222
A survey of thrombosis prophylaxis use in patients undergoing arthroscopic surgery	218
Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature	206
Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency vka anticoagulation reversal	204
Risk of recurrence of unusual site venous thromboembolism	203
Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome	183
Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: A longitudinal study during atorvastatin treatment	181
PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis	178
Optimal treatment duration of venous thrombosis	176
incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio.	175
Impact of neutrophils to lymphocytes ratio on major clinical outcomes in patients with acute coronary syndromes: A systematic review and meta-analysis of the literature	172
Patient selection for thromboprophylaxis in medical inpatients	171
Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry	171
Diagnostic accuracy of lung ultrasound for pulmonary embolism: a systematic review and meta-analysis.	168
Diagnosis and management of venous thromboembolism: Results of a survey on current clinical practice	167
Prognostic stratification of chronic heart failure in elderly population: are cardiopulmonary tests and BNP really valuable?	166
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism.	165
Role of ABO blood group and of other risk factors on the presence of residual vein obstruction after deep-vein thrombosis	164
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature	162
Association between ABCG2 and ABCB1 genes and warfarin stability: a case-control study	162
Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data	162
Prevalence and Clinical History of Incidental, Asymptomatic Pulmonary Embolism: A Meta-Analysis	162
Venous ischemic syndromes	159
Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism	157
Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation	157
Venous and arterial thrombosis in patients with HIV infection	156
Pulmonary Embolism Severity Index Accurately Predicts Long-Term Mortality Rate In Patients Hospitalized For Acute Pulmonary Embolism	156
Warfarin interactions with antibiotics in the ambulatory care setting	154
Duration of anticoagulation after venous thromboembolism in real world clinical practice	154
A clinical score to rule out the concomitant presence of deep vein thrombosis in patients presenting with superficial vein thrombosis: The ICARO study	154
Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens	154
Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy	154
Factors associated with anticoagulation prescription in elderly patients with atrial fibrillation	150
Management of primary care patients with suspected deep vein thrombosis: use of a therapeutic dose of low-molecular-weight heparin to avoid urgent ultrasonographic evaluation.	150
Statins and secondary prevention of ischemic and hemorrhagic stroke	148
Diagnostic accuracy of magnetic resonance imaging in patients with suspected pulmonary embolism: A bivariate meta-analysis	148
In vitro effects of Apixaban on 5 different cancer cell lines	148
Seasonal and monthly variation in occurrence of hypertensive urgency	147
Gender Difference in Efficacy and Safety of Nonvitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation or Venous Thromboembolism: A Systematic Review and a Meta-Analysis of the Literature	147
Emergency reversal of anticoagulation with vitamin K antagonists with 3-factor prothrombin complex concentrates in patients with major bleeding	146
Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians	146
Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis	145
Predictors of residual venous obstruction after deep vein thrombosis of the lower limbs: a prospective cohort study	144
The prevention and treatment of venous thromboembolism in pregnancy	143
Presence of residual thromboemboli at least six months after a first episode of symptomatic pulmonary embolism: do perfusion scintigraphy and angio-computed tomography agree?	142
Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3-month rosuvastatin treatment	142
Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature	142
Intracranial bleeding risk after minor traumatic brain injury in patients on antithrombotic drugs	142
The role of inherited thrombophilia in patients with isolated pulmonary embolism: a systematic review and a meta-analysis of the literature	141
Low ankle-brachial index predicts an adverse 1-year outcome after acute coronary and cerebrovascular events	141
Pulmonary embolism prognostic factors and length of hospital stay: A cohort study	141
Brain natriuretic peptide and preclinical chronic thromboembolic pulmonary hypertension.	140
Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage	140
Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: A multicenter retrospective cohort study	139
Statins for acute ischemic stroke	139
sRAGE and early signs of cardiac target organ damage in mild hypertensives	139
The role of thrombolytic therapy in pulmonary embolism	138
Low-molecular -weight heparin in pregnancies after ART -A retrospective study-	138
Prevention of in-hospital VTE: why can't we do better?	137
How I treat splanchnic vein thrombosis	137
Is diabetes a hypercoagulable state? A critical appraisal	137
The effect of thyroid autoantibodies on warfarin stability	136
Italian intersociety consensus on DOAC use in internal medicine	136
The initial phase of oral anticoagulation with warfarin in outpatients with deep venous thrombosis.	135
Clinical utility of antithrombotic prophylaxis in ART procedures: an Italian experience	134
ABO blood group and vascular disease: an update	134
Recurrence of ICH after resumption of anticoagulation with VK antagonists: CHIRONE Study	134
In-hospital mortality due to pulmonary embolism in patients with Alzheimer disease: A sex effect?	134
Antithrombotic and fibrinolytic drugs for retinal vein occlusion: a systematic review and a call for action.	133
JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis.	133
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature: a reply to a rebuttal	132
Clinical Pregnancies and Live Births in women approaching ART: a follow-up analysis of 157 women after thrombophilia screening	131
Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes	131
Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism: Comment	131
Neutrophil-to-lymphocyte ratio: A new prognostic factor even in patients with heart failure	131
Antithrombin levels and the risk of a first episode of venous thromboembolism: a case-control study	130
Association between the metabolic syndrome, its individual components, and unprovoked venous thromboembolism: Results of a patient-level meta-analysis	130
American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy	130
Management of hypertension in overweight and obese patients: a practical guide for clinicians.	129
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases	129
Metabolic syndrome and hyperhomocysteinemia in patients with deep vein thrombosis: a case-control study	128
Nonadherence with INR monitoring and anticoagulant complications	127
Direct oral anticoagulants for superficial-vein thrombosis	127
Inferior vena cava filter in patients with venous thromboembolism and major bleeding events: building the evidence	126
Risk of Thromboembolism, Recurrent Hemorrhage, and Death after Warfarin Therapy Interruption for Gastrointestinal Tract Bleeding	126
Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry	125
Venous thromboembolism and arterial thromboembolism. Many similarities, far beyond thrombosis per se.	124
The role of the metabolic syndrome in patients with provoked venous thromboembolic events	124
Lipoprotein(a) as a Risk Factor for Venous Thromboembolism: A Systematic Review and Meta-analysis of the Literature	124
An unusual case of cerebral vein thrombosis in a patient with giant cell arteritis	123
A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program.	123
Atypical case of Acute Coronary Syndrome due to Coronary-Pulmonary Steal Syndrome secondary to Pulmonary Embolism.	122
American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients	122
Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study.	121
A prospective validation of the Bova score in normotensive patients with acute pulmonary embolism	121
Evaluation of right ventricular function in patients with a previous episode of pulmonary embolism using tissue Doppler imaging.	120
Location of venous thrombosis in patients with FVL or prothrombin G20210A mutations: Systematic review and meta-analysis	120
Natural anticoagulants deficiency and the risk of venous thromboembolism: A meta-analysis of observational studies	120
Prevalence of renal failure and use of antithrombotic prophylaxis among medical inpatients at increased risk of venous thromboembolic events.	119
Statins, fibrates, and venous thromboembolism: a meta-analysis.	119
Totale	14.604

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	104.451
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	104.451

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2018/2019	4.104	0	0	609	12	16	6	37	281	39	473	1.012	1.619
2019/2020	8.877	404	394	476	1.754	653	965	1.231	1.043	721	571	169	496
2020/2021	7.072	145	653	769	696	410	734	291	622	840	459	575	878
2021/2022	4.040	404	544	187	104	220	173	325	216	230	727	411	499
2022/2023	4.540	482	207	319	379	303	959	51	607	660	276	166	131
2023/2024	3.616	1.244	1.318	1.054	0	0	0	0	0	0	0	0	0
Totale													36.573